Gilead Sciences (GILD) Receives a Buy from Mizuho Securities


In a report released today, Salim Syed from Mizuho Securities assigned a Buy rating to Gilead Sciences (GILD), with a price target of $88. The company’s shares closed yesterday at $64.92.

According to TipRanks.com, Syed is a 3-star analyst with an average return of 1.6% and a 51.6% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Wave Life Sciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $82.36 average price target, a 26.9% upside from current levels. In a report issued on March 14, BMO Capital also initiated coverage with a Buy rating on the stock with a $78 price target.

See today’s analyst top recommended stocks >>

Based on Gilead Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.78 billion and net profit of $3 million. In comparison, last year the company earned revenue of $5.98 billion and had a GAAP net loss of $3.87 billion.

Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. Last month, Gayle Wilson, a Director at GILD sold 19,068 shares for a total of $1,278,891.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts